Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
285 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Bladder Cancer - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Bladder Cancer - Pipeline Review, H2 2014', provides an overview of the Bladder Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Bladder Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bladder Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Bladder Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Bladder Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Bladder Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Bladder Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Bladder Cancer Overview 10 Therapeutics Development 11 Pipeline Products for Bladder Cancer - Overview 11 Pipeline Products for Bladder Cancer - Comparative Analysis 12 Bladder Cancer - Therapeutics under Development by Companies 13 Bladder Cancer - Therapeutics under Investigation by Universities/Institutes 18 Bladder Cancer - Pipeline Products Glance 19 Late Stage Products 19 Clinical Stage Products 20 Early Stage Products 21 Unknown Stage Products 22 Bladder Cancer - Products under Development by Companies 23 Bladder Cancer - Products under Investigation by Universities/Institutes 27 Bladder Cancer - Companies Involved in Therapeutics Development 28 Shionogi & Co., Ltd. 28 AstraZeneca PLC 29 Eli Lilly and Company 30 Viralytics Ltd. 31 GlaxoSmithKline plc 32 Bioniche Life Sciences, Inc. 33 Bavarian Nordic A/S 34 Biotest AG 35 Daiichi Sankyo Company, Limited 36 Merck & Co., Inc. 37 Samyang Holdings Corporation 38 Astellas Pharma Inc. 39 Eisai Co., Ltd. 40 Marina Biotech, Inc. 41 Genmab A/S 42 Celgene Corporation 43 Bayer AG 44 Advaxis, Inc. 45 Evotec AG 46 Immunomedics, Inc. 47 Alnylam Pharmaceuticals, Inc. 48 Oncogenex Pharmaceuticals, Inc. 49 Dendreon Corporation 50 Sanochemia Pharmazeutika AG 51 OncoTherapy Science, Inc. 52 Quest PharmaTech Inc. 53 Synta Pharmaceuticals Corp. 54 Med Discovery SA 55 Hutchison MediPharma Limited 56 Altor BioScience Corporation 57 Telormedix SA 58 Gene Signal International SA 59 Merrimack Pharmaceuticals, Inc. 60 Innate Therapeutics Limited 61 Stemline Therapeutics, Inc. 62 BioCancell Therapeutics, Inc. 63 AndroScience Corporation 64 Serum Institute of India Limited 65 Dompe Farmaceutici S.p.A. 66 NuCana BioMed Limited 67 Polaris Group 68 Serometrix, LLC 69 Regulon Inc. 70 SentoClone International AB 71 Optimum Therapeutics, LLC 72 Lipella Pharmaceuticals, Inc. 73 APIM Therapeutics AS 74 EntreChem, S.L. 75 Immunservice GmbH 76 Qu Biologics Inc. 77 Panacela Labs, Inc. 78 Tolero Pharmaceuticals, Inc. 79 Oncopeptides AB 80 DormaTarg, Inc. 81 AlphaMab Co., Ltd 82 Mirati Therapeutics Inc. 83 Bladder Cancer - Therapeutics Assessment 84 Assessment by Monotherapy Products 84 Assessment by Combination Products 85 Assessment by Target 86 Assessment by Mechanism of Action 90 Assessment by Route of Administration 94 Assessment by Molecule Type 96 Drug Profiles 99 pembrolizumab - Drug Profile 99 apatorsen - Drug Profile 101 mocetinostat - Drug Profile 103 paclitaxel-loaded polymeric micelle - Drug Profile 106 paclitaxel - Drug Profile 108 ramucirumab - Drug Profile 111 ALT-801 - Drug Profile 116 imiquimod - Drug Profile 118 BC-819 - Drug Profile 119 lapuleucel-t - Drug Profile 121 AZD-4547 - Drug Profile 123 SentoClone - Drug Profile 125 astuprotimut-R - Drug Profile 127 recMAGE-A3 + AS15 - Drug Profile 128 CV-301 - Drug Profile 130 IMMU-132 - Drug Profile 131 S-588410 - Drug Profile 132 eribulin mesylate - Drug Profile 133 indatuximab ravtansine - Drug Profile 137 CVA-21 - Drug Profile 139 afuresertib hydrochloride + trametinib dimethyl sulfoxide - Drug Profile 143 MMD-37K - Drug Profile 145 patritumab - Drug Profile 146 HuMax-TF-ADC - Drug Profile 148 PVP Hypericin - Drug Profile 149 MM-111 - Drug Profile 150 NUC-1031 - Drug Profile 152 AZD-5312 - Drug Profile 154 ASG-15ME - Drug Profile 155 AGS-15E - Drug Profile 156 GSK-2849330 - Drug Profile 157 BAY-1163877 - Drug Profile 158 MDRG-01 - Drug Profile 159 MDP-01 - Drug Profile 160 Mycobacterial Cell Wall-DNA Complex Program - Drug Profile 161 OGX-225 - Drug Profile 162 SL-601 - Drug Profile 163 TMX-202 - Drug Profile 164 BC-821 - Drug Profile 165 MDR-09521 - Drug Profile 166 SL-052 - Drug Profile 167 aganirsen - Drug Profile 169 pegargiminase - Drug Profile 171 cisplatin liposomal - Drug Profile 174 MIS-416 - Drug Profile 176 EC-7072 - Drug Profile 178 RNAi Oligonucleotide for Bladder Cancer - Drug Profile 179 Mobilan - Drug Profile 180 ASC-JM.Z1 - Drug Profile 182 ATX-101 - Drug Profile 183 LNP-dsP21-322-2'F - Drug Profile 184 TP-3654 - Drug Profile 185 Melflufen - Drug Profile 186 DT-310 - Drug Profile 188 DT-320 - Drug Profile 189 DT-330 - Drug Profile 190 Recombinant Protein for Bladder Cancer and GBM - Drug Profile 191 Monoclonal Antibodies to Inhibit N-Cadherin for Bladder and Metastatic Hormone Refractory Prostate Cancers - Drug Profile 192 ICT-2700 - Drug Profile 193 Lm-LLO-ISG15 - Drug Profile 194 HMPL-453 - Drug Profile 196 BV-2711 - Drug Profile 197 OTS-964 - Drug Profile 198 HDC-SN-38 - Drug Profile 199 Drugs to Antagonize CXCR1/2 for Bladder and Prostate Cancer - Drug Profile 201 suramin hexasodium - Drug Profile 202 SX-MTR1 - Drug Profile 204 QBECP SSI - Drug Profile 205 KN-014 - Drug Profile 206 Small Molecules to Inhibit CD147 for Immunology, Oncology, Womens Health and Musculoskeletal Disorders - Drug Profile 207 Bladder Cancer Vaccine - Drug Profile 208 Drug for Bladder Cancer - Drug Profile 209 MDNA-55 - Drug Profile 210 Drugs to Inhibit FGFR3 for Cancer - Drug Profile 211 Small Molecules to Activate Caspase 3 and Caspase 9 for Bladder and Urinary Tract Cancer - Drug Profile 212 ISANIL-02 - Drug Profile 213 Bladder Cancer - Recent Pipeline Updates 214 Bladder Cancer - Dormant Projects 267 Bladder Cancer - Discontinued Products 269 Bladder Cancer - Product Development Milestones 270 Featured News & Press Releases 270 Appendix 278 Methodology 278 Coverage 278 Secondary Research 278 Primary Research 278 Expert Panel Validation 278 Contact Us 279 Disclaimer 279
List of Tables Number of Products under Development for Bladder Cancer, H2 2014 17 Number of Products under Development for Bladder Cancer - Comparative Analysis, H2 2014 18 Number of Products under Development by Companies, H2 2014 20 Number of Products under Development by Companies, H2 2014 (Contd..1) 21 Number of Products under Development by Companies, H2 2014 (Contd..2) 22 Number of Products under Development by Companies, H2 2014 (Contd..3) 23 Number of Products under Investigation by Universities/Institutes, H2 2014 24 Comparative Analysis by Late Stage Development, H2 2014 25 Comparative Analysis by Clinical Stage Development, H2 2014 26 Comparative Analysis by Early Stage Development, H2 2014 27 Comparative Analysis by Unknown Stage Development, H2 2014 28 Products under Development by Companies, H2 2014 29 Products under Development by Companies, H2 2014 (Contd..1) 30 Products under Development by Companies, H2 2014 (Contd..2) 31 Products under Development by Companies, H2 2014 (Contd..3) 32 Products under Investigation by Universities/Institutes, H2 2014 33 Bladder Cancer - Pipeline by Shionogi & Co., Ltd., H2 2014 34 Bladder Cancer - Pipeline by AstraZeneca PLC, H2 2014 35 Bladder Cancer - Pipeline by Eli Lilly and Company, H2 2014 36 Bladder Cancer - Pipeline by Viralytics Ltd, H2 2014 37 Bladder Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 38 Bladder Cancer - Pipeline by Bioniche Life Sciences, Inc., H2 2014 39 Bladder Cancer - Pipeline by Bavarian Nordic A/S, H2 2014 40 Bladder Cancer - Pipeline by Biotest AG, H2 2014 41 Bladder Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 42 Bladder Cancer - Pipeline by Merck & Co., Inc., H2 2014 43 Bladder Cancer - Pipeline by Samyang Holdings Corporation, H2 2014 44 Bladder Cancer - Pipeline by Astellas Pharma Inc., H2 2014 45 Bladder Cancer - Pipeline by Eisai Co., Ltd ., H2 2014 46 Bladder Cancer - Pipeline by Marina Biotech, Inc., H2 2014 47 Bladder Cancer - Pipeline by Genmab A/S, H2 2014 48 Bladder Cancer - Pipeline by Celgene Corporation, H2 2014 49 Bladder Cancer - Pipeline by Bayer AG, H2 2014 50 Bladder Cancer - Pipeline by Advaxis, Inc., H2 2014 51 Bladder Cancer - Pipeline by Evotec AG, H2 2014 52 Bladder Cancer - Pipeline by Immunomedics, Inc., H2 2014 53 Bladder Cancer - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2014 54 Bladder Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H2 2014 55 Bladder Cancer - Pipeline by Dendreon Corporation, H2 2014 56 Bladder Cancer - Pipeline by Sanochemia Pharmazeutika AG, H2 2014 57 Bladder Cancer - Pipeline by OncoTherapy Science, Inc., H2 2014 58 Bladder Cancer - Pipeline by Quest PharmaTech Inc., H2 2014 59 Bladder Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2014 60 Bladder Cancer - Pipeline by Med Discovery SA, H2 2014 61 Bladder Cancer - Pipeline by Hutchison MediPharma Limited, H2 2014 62 Bladder Cancer - Pipeline by Altor BioScience Corporation, H2 2014 63 Bladder Cancer - Pipeline by Telormedix SA, H2 2014 64 Bladder Cancer - Pipeline by Gene Signal International SA, H2 2014 65 Bladder Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2014 66 Bladder Cancer - Pipeline by Innate Therapeutics Limited, H2 2014 67 Bladder Cancer - Pipeline by Stemline Therapeutics, Inc., H2 2014 68 Bladder Cancer - Pipeline by BioCancell Therapeutics, Inc., H2 2014 69 Bladder Cancer - Pipeline by AndroScience Corporation, H2 2014 70 Bladder Cancer - Pipeline by Serum Institute of India Limited, H2 2014 71 Bladder Cancer - Pipeline by Dompe Farmaceutici S.p.A., H2 2014 72 Bladder Cancer - Pipeline by NuCana BioMed Limited, H2 2014 73 Bladder Cancer - Pipeline by Polaris Group, H2 2014 74 Bladder Cancer - Pipeline by Serometrix, LLC, H2 2014 75 Bladder Cancer - Pipeline by Regulon Inc., H2 2014 76 Bladder Cancer - Pipeline by SentoClone International AB, H2 2014 77 Bladder Cancer - Pipeline by Optimum Therapeutics, LLC, H2 2014 78 Bladder Cancer - Pipeline by Lipella Pharmaceuticals, Inc., H2 2014 79 Bladder Cancer - Pipeline by APIM Therapeutics AS, H2 2014 80 Bladder Cancer - Pipeline by EntreChem, S.L., H2 2014 81 Bladder Cancer - Pipeline by Immunservice GmbH, H2 2014 82 Bladder Cancer - Pipeline by Qu Biologics Inc., H2 2014 83 Bladder Cancer - Pipeline by Panacela Labs, Inc., H2 2014 84 Bladder Cancer - Pipeline by Tolero Pharmaceuticals, Inc., H2 2014 85 Bladder Cancer - Pipeline by Oncopeptides AB, H2 2014 86 Bladder Cancer - Pipeline by DormaTarg, Inc., H2 2014 87 Bladder Cancer - Pipeline by AlphaMab Co., Ltd, H2 2014 88 Bladder Cancer - Pipeline by Mirati Therapeutics Inc., H2 2014 89 Assessment by Monotherapy Products, H2 2014 90 Assessment by Combination Products, H2 2014 91 Number of Products by Stage and Target, H2 2014 94 Number of Products by Stage and Mechanism of Action, H2 2014 98 Number of Products by Stage and Route of Administration, H2 2014 101 Number of Products by Stage and Molecule Type, H2 2014 104 Bladder Cancer Therapeutics - Recent Pipeline Updates, H2 2014 220 Bladder Cancer - Dormant Projects, H2 2014 273 Bladder Cancer - Dormant Projects (Contd..1), H2 2014 274 Bladder Cancer - Discontinued Products, H2 2014 275
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
